Table 2.

Percent Maximal Cutaneous Vascular Conductance Values

Limb and Time Point	Sex	Phase	Treatment	%CVC	SD
Forearm Baseline	FEMALE	MID-LUTEAL	CONTROL	7.66%	3.70%
			EMLA	2.18%*	1.81%
		EARLY FOLLICULAR	CONTROL	8.36%	3.66%
			EMLA	2.68%*	1.70%
	MALE		CONTROL	9.98%	3.77%
			EMLA	4.28%*	3.15%
Leg Baseline	FEMALE	MID-LUTEAL	CONTROL	6.72%	2.28%
			EMLA	7.40%	2.19%
		EARLY FOLLICULAR	CONTROL	6.20%	1.76%
			EMLA	7.93%	3.06%
	MALE		CONTROL	11.25%	6.29%
			EMLA	11.45%	4.21%
Forearm Rapid Initial Response	FEMALE	MID-LUTEAL	CONTROL	74.32%	9.09%
			EMLA	49.72%*	18.59%
		EARLY FOLLICULAR	CONTROL	78.16%	5.85%
			EMLA	52.66%*	16.35%
	MALE		CONTROL	74.90%	10.07%
			EMLA	58.36%*	17.00%
Leg Rapid Initial Response	FEMALE	MID-LUTEAL	CONTROL	66.33%	14.53%
			EMLA	45.10%*	14.73%
		EARLY FOLLICULAR	CONTROL	64.50%	10.97%
			EMLA	50.10%	21.52%
	MALE		CONTROL	63.65%	10.06%
			EMLA	53.71%	9.44%
Forearm Sustained Response	FEMALE	MID-LUTEAL	CONTROL	87.89%	8.82%
			EMLA	87.55%	8.04%
		EARLY FOLLICULAR	CONTROL	90.24%	3.62%
			EMLA	88.32%	5.73%
	MALE		CONTROL	87.51%	6.40%
			EMLA	84.24%	5.90%

Phase = phase of the menstrual cycle; %CVC = Percentage of maximal cutaneous vascular conductance;

^*indicates that p < 0.05 when compared to control sites.